Clinical Research Directory

Inclusion Criteria * Dose escalation phase: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumor who progressed on or are intolerant of standard therapy; * Dose expansion phase: patients with UC, GC/GEJ, or IHCC harboring specific FGFR gene alterations; * Age 18 to 75 years; * Those who are able to give written informed consent, and able to comply with protocol-specified visits and related procedures; * Ability to swallow study drug; * ECOG PS of 0 or 1; * Measurable lesion according to RECIST v1.1, refer to the protocol; * Adequate organ and bone marrow function; * Life expectancy ≥ 12 weeks; * Female patients or male patients with partners of childbearing potential must take effective contraceptive measures per the protocol. Exclusion Criteria * Patients who previously received selective FGFR targeting therapy; * Concurrent participation in another interventional clinical study, excluding those in the follow-up period and have not recently received investigational intervention; * Current or previous history of central nervous system (CNS) metastases； * Current or previous history of retinal detachment； * Known history of primary immunodeficiency; * Female patients who are pregnant or lactating； * Patients who in the opinion of the investigator may be unsuitable for participating in the study; * Patients with acute or chronic active hepatitis B or C infection; * Known human immunodeficiency virus (HIV) infection and syphilis infection； * Clinically significant cardiovascular disease such as congestive heart failure or arrhythmia； * Uncontrolled hypertension despite optimal medical management； * Received live vaccine within 30 days before the first dose of study drug(s); * Those who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first study treatment or who are expected to be in need of major surgery; those with unhealed wounds, ulcers or fractures.